Treatment Avenues in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Split-gender Pharmacogenomic Study of Gene-expression Modules.
Jeffrey, Mary G, Nathanson, Lubov, Aenlle, Kristina et al. · Clinical therapeutics · 2019 · DOI
Quick Summary
Researchers studied blood samples from 33 ME/CFS patients and 21 healthy people to look for differences in how their genes were working. They found that ME/CFS appears to involve problems with the immune system (the body's defense mechanism) and how cells produce energy. By matching these gene differences with existing FDA-approved drugs, they identified immunosuppressant medications as potential candidates that might help reduce ME/CFS symptoms.
Why It Matters
This study provides molecular evidence that immune dysregulation plays a role in ME/CFS symptoms, offering a mechanistic rationale for exploring immune-modulating treatments. Repositioning existing FDA-approved drugs could accelerate access to potential therapies while avoiding lengthy drug development timelines.
Observed Findings
Immune regulation and mitochondrial dysfunction modules showed differential expression in males with small effect sizes.
In females, immune, cardiac, and blood-related modules were differentially expressed with effect sizes ranging from very small to intermediate (Cohen δ: 0.147-0.532).
B-cell receptors, T-cell receptors, TNF-α, and TGF-β modules were strongly correlated with multiple fatigue severity measures.
Gene expression patterns differed between males and females, suggesting sex-based biological differences in ME/CFS presentation.
Pharmacogenomic analysis identified immunosuppressants as drugs with potential to target identified dysregulated pathways.
Inferred Conclusions
ME/CFS symptoms appear to be perpetuated by immune dysregulation affecting B-cells, T-cells, and inflammatory signaling.
Immune modulation-based treatment strategies may be a rational therapeutic approach for ME/CFS.
Sex differences in gene expression patterns suggest that males and females may require different treatment approaches.
Remaining Questions
Do the identified immunosuppressants actually reduce fatigue and improve function in ME/CFS patients when tested in clinical trials?
Are the observed gene expression changes the cause of ME/CFS symptoms or a consequence of the disease?
What This Study Does Not Prove
This study does not prove that immunosuppressants will actually work as treatments—it only identifies them as candidates based on gene expression patterns. It cannot establish causation or determine whether the observed immune changes cause ME/CFS symptoms or result from them. The findings have not been validated in clinical trials.